Over 10 years experience with finding new drug combinations
Qameleon Therapeutics is a spin off of the Netherlands Cancer Institute established in 2015 to accelerate finding drug combinations that overcome initial or acquired resistance to targeted therapy in oncology
At Qameleon we have access to 10+ years of expertise in synthetic lethal screens. We develop custom shRNA libraries for in house screens that are optimized for the mechanism of action.
shRNA data in combination with additional pre clinical data can be used to justify combination therapy trials
KEY BENEFITS OF OUR APPROACH
Maximizing outcome, minimizing off target hits
Companies we have worked with
- Eli Lilly